Regeneron/REGN

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Regeneron

Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company helps in accelerating and improving the traditional drug development process through its VelociSuite technologies, such as VelocImmune, which uses genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center. Its marketed products include EYLEA (aflibercept) Injection; Dupixent (dupilumab) Injection; Libtayo (cemiplimab) Injection; Praluent (alirocumab) Injection; Kevzara (sarilumab) Injection, and others.

Ticker

REGN

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

Headquarters

Tarrytown, United States

Employees

13,450

Regeneron Metrics

BasicAdvanced
$108B
Market cap
28.95
P/E ratio
$33.86
EPS
0.12
Beta
-
Dividend rate
$108B
0.12
$998.33
$684.81
9.3
5.27
4.512
10.016
10.016
28.753
11.98%
15.28%
13.36%
28.947
8.244
4.002
4.165
27.482
5.90%
-8.00%
15.57%
4.44%

What the Analysts think about Regeneron

Analyst Ratings

Majority rating from 29 analysts.
Buy

Regeneron Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
22.95% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$3.1B
-8.42%
Net income
$722M
-37.74%
Profit margin
22.95%
-32.02%

Regeneron Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 5.38%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
$10.24
$11.59
$11.86
$9.55
-
Expected
$9.84
$10.72
$10.73
$10.09
$10.59
Surprise
4.03%
8.13%
10.53%
-5.38%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Regeneron stock?

Regeneron (REGN) has a market cap of $108B as of June 22, 2024.

What is the P/E ratio for Regeneron stock?

The price to earnings (P/E) ratio for Regeneron (REGN) stock is 28.95 as of June 22, 2024.

Does Regeneron stock pay dividends?

No, Regeneron (REGN) stock does not pay dividends to its shareholders as of June 22, 2024.

When is the next Regeneron dividend payment date?

Regeneron (REGN) stock does not pay dividends to its shareholders.

What is the beta indicator for Regeneron?

Regeneron (REGN) has a beta rating of 0.12. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Regeneron stock price target?

The target price for Regeneron (REGN) stock is $1060.68, which is NaN% below the current price of $. This is an average based on projections from 24 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Regeneron stock

Buy or sell Regeneron stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing